Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0218

Sigma-Aldrich

Bropirimine

≥98% (HPLC)

Synonym(s):

2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone, NSC 149027, PNU 54461, U 54461, U 54461S

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C10H8BrN3O
CAS Number:
56741-95-8
Molecular Weight:
266.09
MDL number:
MFCD01689128
UNSPSC Code:
41116107
PubChem Substance ID:
329825238
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥5 mg/mL (warm DMSO)

storage temp.

room temp

SMILES string

NC1=NC(=O)C(Br)=C(N1)c2ccccc2

InChI

1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)

InChI key

CIUUIPMOFZIWIZ-UHFFFAOYSA-N

Application

Bropirimine, an immunostimulating agent and toll like receptor (TLR7) agonist, is used in comparison with other TLR7 agonists such as imiquimod, R-848, loxoribine in interferon cell signaling research. Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research.

Biochem/physiol Actions

Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sandra Demaria et al.
Oncoimmunology, 2(10), e25997-e25997 (2014-01-10)
Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial
M A Wynalda et al.
Xenobiotica; the fate of foreign compounds in biological systems, 33(10), 999-1011 (2003-10-14)
1. The antitumour agent bropirimine undergoes significant Phase II conjugation in vivo. Incubation of [14C]bropirimine with human liver microsomes resulted in the formation of a single product peak (M1) using high-performance liquid chromatography with radiochemical detection and was tentatively assigned
J A Witjes
European urology, 31 Suppl 1, 27-30 (1997-01-01)
To explore new treatment strategies in high-risk superficial bladder cancer patients, such as recurrent carcinoma in situ (CIS) or pT1 transitional cell carcinoma after intravesical bacillus Calmette-Guérin (BCG). Mechanism of action, pharmacology and the results of clinical phase I and
M Shaw et al.
Methods and findings in experimental and clinical pharmacology, 20(2), 111-114 (1998-05-30)
Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression
Current and new strategies in immunotherapy for superficial bladder cancer.
Frank G E Perabo et al.
Urology, 64(3), 409-421 (2004-09-08)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service